Mark Pilkinton
Vanderbilt University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Pilkinton.
Clinical Cancer Research | 2016
Sherene Loi; Sathana Dushyanthen; Paul A. Beavis; Roberto Salgado; Carsten Denkert; Peter Savas; Susan E. Combs; David L. Rimm; Jennifer M. Giltnane; Monica V. Estrada; Violeta Sanchez; Melinda E. Sanders; Rebecca S. Cook; Mark Pilkinton; S. Mallal; Kai Wang; Vincent A. Miller; Philip J. Stephens; Roman Yelensky; Franco Doimi; Henry Gomez; Sergey Ryzhov; Phillip K. Darcy; Carlos L. Arteaga; Justin M. Balko
Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways affecting these features are lacking. Experimental Design: We analyzed TILs in the RD of clinically and molecularly characterized TNBCs after NAC and explored therapeutic strategies targeting combinations of MEK inhibitors with PD-1/PD-L1–targeted immunotherapy in mouse models of breast cancer. Results: Presence of TILs in the RD was significantly associated with improved prognosis. Genetic or transcriptomic alterations in Ras–MAPK signaling were significantly correlated with lower TILs. MEK inhibition upregulated cell surface MHC expression and PD-L1 in TNBC cells both in vivo and in vitro. Moreover, combined MEK and PD-L1/PD-1 inhibition enhanced antitumor immune responses in mouse models of breast cancer. Conclusions: These data suggest the possibility that Ras–MAPK pathway activation promotes immune-evasion in TNBC, and support clinical trials combining MEK- and PD-L1–targeted therapies. Furthermore, Ras/MAPK activation and MHC expression may be predictive biomarkers of response to immune checkpoint inhibitors. Clin Cancer Res; 22(6); 1499–509. ©2015 AACR.
Circulation Research | 2016
Hana A. Itani; Liang Xiao; Mohamed A. Saleh; Jing Wu; Mark Pilkinton; Bethany L. Dale; Natalia R. Barbaro; Jason D. Foss; Annet Kirabo; Kim R Montaniel; Allison E. Norlander; Wei Chen; Ryosuke Sato; L G Navar; S. Mallal; Meena S. Madhur; Kenneth E. Bernstein; David G. Harrison
RATIONALE Accumulating evidence supports a role of adaptive immunity and particularly T cells in the pathogenesis of hypertension. Formation of memory T cells, which requires the costimulatory molecule CD70 on antigen-presenting cells, is a cardinal feature of adaptive immunity. OBJECTIVE To test the hypothesis that CD70 and immunologic memory contribute to the blood pressure elevation and renal dysfunction mediated by repeated hypertensive challenges. METHODS AND RESULTS We imposed repeated hypertensive challenges using either N(ω)-nitro-L-arginine methyl ester hydrochloride (L-NAME)/high salt or repeated angiotensin II stimulation in mice. During these challenges effector memory T cells (T(EM)) accumulated in the kidney and bone marrow. In the L-NAME/high-salt model, memory T cells of the kidney were predominant sources of interferon-γ and interleukin-17A, known to contribute to hypertension. L-NAME/high salt increased macrophage and dendritic cell surface expression of CD70 by 3- to 5-fold. Mice lacking CD70 did not accumulate T(EM) cells and did not develop hypertension to either high salt or the second angiotensin II challenge and were protected against renal damage. Bone marrow-residing T(EM) cells proliferated and redistributed to the kidney in response to repeated salt feeding. Adoptively transferred T(EM) cells from hypertensive mice homed to the bone marrow and spleen and expanded on salt feeding of the recipient mice. CONCLUSIONS Our findings illustrate a previously undefined role of CD70 and long-lived T(EM) cells in the development of blood pressure elevation and end-organ damage that occur on delayed exposure to mild hypertensive stimuli. Interventions to prevent repeated hypertensive surges could attenuate formation of hypertension-specific T(EM) cells.
Vaccine | 2017
Mark Pilkinton; Katherine J. Nicholas; Christian M. Warren; Rita M. Smith; Sandra M. Yoder; H. Keipp Talbot; Spyros A. Kalams
BACKGROUND Influenza related morbidity and mortality disproportionately impacts older adults. The serologic response to vaccine is diminished in older adults; however, high dose inactivated influenza vaccine (HD IIV) has shown improved rates of seroconversion compared to standard dose (SD IIV). We hypothesize this may be due to the superior ability of high dose vaccine to activate T follicular helper (Tfh) cells and provide B cell dependent T cell help. METHODS We measured peripheral Tfh (pTfh) activation in 50 community dwelling adults 65years or older who were randomly assigned to receive either the HD IIV or SD IIV. RESULTS The HD vaccination elicited significantly higher levels of ICOS expression on pTfh cells, at day 7 compared to SD vaccination (p=0.02). The magnitude of the increase in ICOS+ pTfh cells from baseline to day 7 was predictive of seroconversion for both influenza A and B vaccination. CONCLUSION Strong Tfh activation in response to influenza vaccination forecasts successful seroconversion in older adults, and HD IIV elicits greater Tfh activation than SD IIV. Future vaccine studies should focus on ways to further optimize the Tfh response.
Journal of the American Geriatrics Society | 2015
Mark Pilkinton; H. Keipp Talbot
Vaccination is a vital component of routine preventative health. Older adults can potentially benefit most from vaccines because they have greater susceptibility to disease and associated complications. The number of infections covered and the types of vaccines available has grown significantly in recent years. Although this represents tremendous progress, it can also result in confusion and missed opportunities to provided recommended vaccinations. This review summarizes the current guidelines for vaccination of older adults and highlights the latest innovations.
Journal of Acquired Immune Deficiency Syndromes | 2017
John R. Koethe; Wyatt J. McDonnell; Arion Kennedy; Chike O. Abana; Mark Pilkinton; Ian Setliff; Ivelin S. Georgiev; Louise Barnett; Cindy C. Hager; Rita M. Smith; Spyros A. Kalams; Alyssa H. Hasty; S. Mallal
Background: Adverse viral and medication effects on adipose tissue contribute to the development of metabolic disease in HIV-infected persons, but T cells also have a central role modulating local inflammation and adipocyte function. We sought to characterize potentially proinflammatory T-cell populations in adipose tissue among persons on long-term antiretroviral therapy and assess whether adipose tissue CD8+ T cells represent an expanded, oligoclonal population. Methods: We recruited 10 HIV-infected, non-diabetic, overweight or obese adults on efavirenz, tenofovir, and emtricitabine for >4 years with consistent viral suppression. We collected fasting blood and subcutaneous abdominal adipose tissue to measure the percentage of CD4+ and CD8+ T cells expressing activation, exhaustion, late differentiation/senescence, and memory surface markers. We performed T-cell receptor (TCR) sequencing on sorted CD8+ cells. We compared the proportion of each T-cell subset and the TCR repertoire diversity, in blood versus adipose tissue. Results: Adipose tissue had a higher percentage of CD3+CD8+ T cells compared with blood (61.0% vs. 51.7%, P < 0.01) and was enriched for both activated CD8+HLA-DR+ T cells (5.5% vs. 0.9%, P < 0.01) and late-differentiated CD8+CD57+ T cells (37.4% vs. 22.7%, P < 0.01). Adipose tissue CD8+ T cells displayed distinct TCR&bgr; V and J gene usage, and the Shannon Entropy index, a measure of overall TCR&bgr; repertoire diversity, was lower compared with blood (4.39 vs. 4.46; P = 0.05). Conclusions: Adipose tissue is enriched for activated and late-differentiated CD8+ T cells with distinct TCR usage. These cells may contribute to tissue inflammation and impaired adipocyte fitness in HIV-infected persons.
Journal of Immunology | 2017
Chike O. Abana; Mark Pilkinton; Silvana Gaudieri; A. Chopra; Wyatt J. McDonnell; Celestine Wanjalla; Louise Barnett; Rama Gangula; Cindy C. Hager; Dae K. Jung; Brian G. Engelhardt; Madan Jagasia; Paul Klenerman; E. Phillips; David M. Koelle; Spyros A. Kalams; S. Mallal
Select CMV epitopes drive life-long CD8+ T cell memory inflation, but the extent of CD4 memory inflation is poorly studied. CD4+ T cells specific for human CMV (HCMV) are elevated in HIV+ HCMV+ subjects. To determine whether HCMV epitope–specific CD4+ T cell memory inflation occurs during HIV infection, we used HLA-DR7 (DRB1*07:01) tetramers loaded with the glycoprotein B DYSNTHSTRYV (DYS) epitope to characterize circulating CD4+ T cells in coinfected HLA-DR7+ long-term nonprogressor HIV subjects with undetectable HCMV plasma viremia. DYS-specific CD4+ T cells were inflated among these HIV+ subjects compared with those from an HIV− HCMV+ HLA-DR7+ cohort or with HLA-DR7–restricted CD4+ T cells from the HIV-coinfected cohort that were specific for epitopes of HCMV phosphoprotein-65, tetanus toxoid precursor, EBV nuclear Ag 2, or HIV gag protein. Inflated DYS-specific CD4+ T cells consisted of effector memory or effector memory–RA+ subsets with restricted TCRβ usage and nearly monoclonal CDR3 containing novel conserved amino acids. Expression of this near-monoclonal TCR in a Jurkat cell–transfection system validated fine DYS specificity. Inflated cells were polyfunctional, not senescent, and displayed high ex vivo levels of granzyme B, CX3CR1, CD38, or HLA-DR but less often coexpressed CD38+ and HLA-DR+. The inflation mechanism did not involve apoptosis suppression, increased proliferation, or HIV gag cross-reactivity. Instead, the findings suggest that intermittent or chronic expression of epitopes, such as DYS, drive inflation of activated CD4+ T cells that home to endothelial cells and have the potential to mediate cytotoxicity and vascular disease.
Scientific Reports | 2018
Michaela Lucas; Pooja Deshpande; I. James; Andri Rauch; K. Pfafferott; Elouise Gaylard; S. Merani; Anne Plauzolles; Andrew Lucas; Wyatt J. McDonnell; Spyros A. Kalams; Mark Pilkinton; Cody Chastain; Louise Barnett; Amy Prosser; S. Mallal; Karen Fitzmaurice; Heidi E. Drummer; M. Azim Ansari; Vincent Pedergnana; E. Barnes; M. John; Dermot Kelleher; Paul Klenerman; Silvana Gaudieri
Hepatitis C virus (HCV)-specific T cell responses are critical for immune control of infection. Viral adaptation to these responses, via mutations within regions of the virus targeted by CD8+ T cells, is associated with viral persistence. However, identifying viral adaptation to HCV-specific CD4+ T cell responses has been difficult although key to understanding anti-HCV immunity. In this context, HCV sequence and host genotype from a single source HCV genotype 1B cohort (n = 63) were analyzed to identify viral changes associated with specific human leucocyte antigen (HLA) class II alleles, as these variable host molecules determine the set of viral peptides presented to CD4+ T cells. Eight sites across the HCV genome were associated with HLA class II alleles implicated in infection outcome in this cohort (p ≤ 0.01; Fisher’s exact test). We extended this analysis to chronic HCV infection (n = 351) for the common genotypes 1A and 3A. Variation at 38 sites across the HCV genome were associated with specific HLA class II alleles with no overlap between genotypes, suggestive of genotype-specific T cell targets, which has important implications for vaccine design. Here we show evidence of HCV adaptation to HLA class II-restricted CD4+ T cell pressure across the HCV genome in chronic HCV infection without a priori knowledge of CD4+ T cell epitopes.
Diabetes | 2018
Wyatt J. McDonnell; John R. Koethe; S. Mallal; Mark Pilkinton; Annet Kirabo; Magdalene K. Ameka; Matthew A. Cottam; Alyssa H. Hasty; Arion Kennedy
Adipose tissue (AT) CD4+ and CD8+ T cells contribute to obesity-associated insulin resistance. Prior studies identified conserved T-cell receptor (TCR) chain families in obese AT, but the presence and clonal expansion of specific TCR sequences in obesity has not been assessed. We characterized AT and liver CD8+ and CD4+ TCR repertoires of mice fed a low-fat diet (LFD) and high-fat diet (HFD) using deep sequencing of the TCRβ chain to quantify clonal expansion, gene usage, and CDR3 sequence. In AT CD8+ T cells, HFD reduced TCR diversity, increased the prevalence of public TCR clonotypes, and selected for TCR CDR3 regions enriched in positively charged and less polarized amino acids. Although TCR repertoire alone could distinguish between LFD- and HFD-fed mice, these properties of the CDR3 region of AT CD8+ T cells from HFD-fed mice led us to examine the role of negatively charged and nonpolar isolevuglandin (isoLG) adduct-containing antigen-presenting cells within AT. IsoLG-adducted protein species were significantly higher in AT macrophages of HFD-fed mice; isoLGs were elevated in M2-polarized macrophages, promoting CD8+ T-cell activation. Our findings demonstrate that clonal TCR expansion that favors positively charged CDR3s accompanies HFD-induced obesity, which may be an antigen-driven response to isoLG accumulation in macrophages.
The New England Journal of Medicine | 2016
Douglas B. Johnson; Justin M. Balko; Margaret Compton; Spyridon Chalkias; Joshua M. Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R. Alexander; Tyler Bloomer; Jason R. Becker; David Slosky; E. Phillips; Mark Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S. Reshef; Jonathan S. Deutsch; Raquel P. Deering; Benjamin A. Olenchock; Andrew H. Lichtman; Dan M. Roden; Christine E. Seidman; Igor J. Koralnik; Jonathan G. Seidman; Robert D. Hoffman; Janis M. Taube; Luis A. Diaz; Robert A. Anders
The Journal of Allergy and Clinical Immunology | 2018
Katie D. White; Katherine C. Konvinse; Mark Pilkinton; Alec J. Redwood; Jason A. Trubiano; Jonathan G. Peter; Rannakoe Lehloenya; Wen-Hung Chung; Shuen-Iu Hung; Ren-You Pan; A. Chopra; Louise Barnett; Rama Gangula; S. Mallal; E. Phillips